Zenas BioPharma
泽纳仕生物
Zenas BioPharma
Biotech/Healthcare
Zenas Bio is dedicated to developing immunotherapy drugs. It is currently conducting clinical trials of obexelimab for IgG4-related disease (IgG4-RD) and autoimmune diseases.
Latest round: IPO (2024)
Source: ChinaBulls — chinabulls.com
Last updated 2024-09-01
Funding history
Request access to view this section.
Investors
Request access to view this section.
HQ & website
Request access to view this section.
Tags
Request access to view this section.